1-1 of 1
Keywords: Cyclin-dependent kinase inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells

Available to Purchase
Subject Area:
Endocrinology , Neurology and Neuroscience
Francesca Terracciano, Alessia Capone, Andrea Montori, Maria Rinzivillo, Stefano Partelli, Francesco Panzuto, Emanuela Pilozzi, Paolo Giorgio Arcidiacono, Claudio Sette, Gabriele Capurso
Journal: Neuroendocrinology
Neuroendocrinology (2021) 111 (8): 739–751.
https://doi.org/10.1159/000509865
Published Online: 02 July 2020
... in the development of secondary resistance to everolimus in PanNEN cell lines and in metastatic lesions from neuroendocrine neoplasm patients. MYC knockdown restored ER-BON-1 sensitivity to everolimus. Pharmacological inhibition of MYC mediated by the cyclin-dependent kinase inhibitor dinaciclib strongly reduced...
View articletitled, MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells
Open the PDF for MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells in another window